Market Place
Sourcing Support
Tryp, Exopharm Announce Arrangement Completion
01 May 2024 //
ACCESSWIRE
Tryp Updates Exopharm Arrangement, Halts Trading
24 Apr 2024 //
ACCESSWIRE
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
26 Jan 2024 //
ACCESSWIRE
Tryp Announces Significant Milestone in Its Clinical Trial Program for Trp-8803
08 Jan 2024 //
ACCESSWIRE
Tryp Announces First Patient Dosed in Phase 2a for the Treatment of Fibromyalgia
04 Jan 2024 //
ACCESSWIRE
Tryp Announces Signing of Definitive Agreement with Exopharm Limited
11 Dec 2023 //
ACCESSWIRE
Tryp Announces Closing of Private Placement of Unsecured Convertible Notes
20 Nov 2023 //
ACCESSWIRE
Tryp Therapeutics Announces Private Placement of Unsecured Convertible Notes
02 Nov 2023 //
ACCESSWIRE
Tryp Announces Closing of Private Placement of Unsecured Convertible Debentures
11 Oct 2023 //
ACCESSWIRE
Tryp Announces Private Placement of Unsecured Convertible Debentures
04 Oct 2023 //
ACCESSWIRE
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
03 Aug 2023 //
ACCESSWIRE
Tryp Receives Confirmation From FDA To Proceed Ph 2A Trial in Patients With IBS
13 Jul 2023 //
ACCESSWIRE
Tryp seeks FDA approval for trial of psilocybin assisted psychotherapy
25 May 2023 //
CLINICAL TRIALS ARENA
Tryp Therapeutics Submits(IND) to US FDA Ph 2a Trial in Patients With IBS
24 May 2023 //
ACCESSWIRE
Tryp Announces Private Placement of Secured Convertible Debentures
12 Apr 2023 //
ACCESSWIRE
Tryp Completes Psychotherapy Training for Planned Phase 2a Clinical Trial
04 Apr 2023 //
ACCESSWIRE
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial
05 Jan 2023 //
ACCESSWIRE
Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
21 Dec 2022 //
GLOBENEWSWIRE
Tryp Therapeutics Announces Fiscal Year 2022 Financial Results
13 Dec 2022 //
GLOBENEWSWIRE
Tryp Therapeutics Announces Publication of International PCT Patent
03 Oct 2022 //
GLOBENEWSWIRE
Tryp Strengthens Intellectual Property PortfolioProvisional Patent Applications
26 Sep 2022 //
GLOBENEWSWIRE
Tryp Therapeutics Appoints New Chief Operating Officer
23 Jun 2022 //
PRNEWSWIRE
Tryp Shows Results Of 1st Patient Dosed In PII Trial For Binge Eating Disorder
09 Jun 2022 //
PRNEWSWIRE
Tryp initiates subject dosing in Phase II psilocybin-assisted therapy trial
29 Apr 2022 //
CLINICALTRIALSARENA
Tryp Therapeutics Announces Q1 2022 Financial Results
28 Jan 2022 //
PRNEWSWIRE
Tryp Therapeutics Advances Phase 2a Clinical Trial in Binge Eating Disorder
23 Dec 2021 //
PRNEWSWIRE
Tryp Therapeutics Advances Phase 2a Clinical Trial in Binge Eating Disorder
23 Dec 2021 //
PRNEWSWIRE
Tryp Receives Confirmation from FDA to Proceed Phase 2a Study in Fibromyalgia
02 Dec 2021 //
PRNEWSWIRE
Tryp Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
18 Nov 2021 //
PRNEWSWIRE
Tryp Therapeutics Partners with Albany Molecular Research Inc. to Manufacture a Proprietary Psilocybin-based Drug
13 Aug 2020 //
FINANCE YAHOO
